Susquehanna International Group
CERE

Susquehanna International Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Susquehanna International Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-328,100
Closed -$13.4M – 13388
2024
Q2 		$13.4M Buy
328,100
+215,800
+192% +$8.99M ﹤0.01% 2143
2024
Q1 		$4.75M Sell
112,300
-108,300
-49% -$4.55M ﹤0.01% 3708
2023
Q4 		$9.35M Buy
220,600
+166,300
+306% +$4.78M ﹤0.01% 2725
2023
Q3 		$1.19M Sell
54,300
-149,800
-73% -$3.75M ﹤0.01% 6256
2023
Q2 		$6.49M Sell
204,100
-20,800
-9% -$638K ﹤0.01% 3113
2023
Q1 		$5.49M Buy
224,900
+168,500
+299% +$4.95M ﹤0.01% 3329
2022
Q4 		$1.78M Sell
56,400
-76,000
-57% -$2.14M ﹤0.01% 4931
2022
Q3 		$3.74M Buy
132,400
+74,400
+128% +$2.22M ﹤0.01% 3649
2022
Q2 		$1.53M Buy
58,000
+44,700
+336% +$1.27M ﹤0.01% 5470
2022
Q1 		$466K Sell
13,300
-40,200
-75% -$1.17M ﹤0.01% 9171
2021
Q4 		$1.73M Sell
53,500
-10,200
-16% -$360K ﹤0.01% 5852
2021
Q3 		$1.88M Buy
63,700
+40,000
+169% +$1.12M ﹤0.01% 5968
2021
Q2 		$607K Buy
+23,700
New +$339K ﹤0.01% 9126

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Susquehanna International Group's CERE Position: Q3 2024 in Review

Susquehanna International Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 108,832 shares — an estimated $4.45M sold.

Susquehanna International Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $6.17M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Susquehanna International Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 108,832 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.45M.
  • Susquehanna International Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Susquehanna International Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6.17M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.